SWOG S1007: A PHASE III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy with or without Chemotherapy in Patients with One to Three Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score of 25 or Less. RxPONDER; A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
This clinical trial is for patients with lymph node-positive, hormone-receptor positive, HER2 negative breast cancer who also have low to intermediate Oncotype DX recurrence sores.
The purpose of this study is to find out if the Oncotype DX Recurrence Score can help decide whether patients should receive chemotherapy or not. This study is being done in patients with lower Recurrence Scores (25 or less).
If the results of this study show there is a benefit for getting chemotherapy is dependent on the Recurrence Score, the study may be able to identify a Recurrence Score level where chemotherapy may or may not be needed.
Follow-up visits occur every three months for the first two years, then every six months for the next three years. After five years, one follow-up visit per year is required for at least 15 years after starting the study. During treatment, patients are followed more frequently based on protocol requirements.